Dossier
Mwyngil Therapeutics
Coverage of Mwyngil Therapeutics in the Nexus archive.
- STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
Mwyngil Therapeutics, a new biotech startup, is developing obesity treatments without targeting the GLP-1 receptor, which most competitors use. CEO Luba Greenwood, a biotech veteran, emphasized the company's focus on non-GLP-1 approaches to avoid 'me too' drug development in the weight loss market.